Improved care for people with heart and circulatory disease suffering from Covid-19 could soon be available after the British Heart Foundation (BHF) and National Institute for Health Research (NIHR) announced support for six flagship research programmes.
Researchers from across the UK will combine data from hospitals, information about our health and lifestyle, genetic studies, and cutting-edge imaging and artificial intelligence techniques to better understand how the virus affects the heart and circulatory system.
People with heart and circulatory diseases are disproportionally affected by Covid-19. Data from the Office of National Statistics (ONS) has consistently shown heart disease to be among the most common pre-existing health conditions in people who have died with the virus in England and Wales.
Covid-19 has also been shown to damage the heart and blood vessels, and increase the risk of blood clotting and inflammation, which can lead to heart attacks and strokes.
The research projects will address urgent questions, such as who is most at risk, how best to manage Covid-19 infection in people with pre-existing cardiovascular illnesses, and how to prevent the longer term effects that the virus might have on people’s heart and circulation.
Professor Sir Nilesh Samani, Medical Director at the British Heart Foundation, said:
“This virus may be a respiratory infection, but the most common underlying health conditions in those who die are cardiovascular. People with heart disease are at higher risk of dying from the virus and the risk for people with diabetes is two to three times higher than the general population. We are also rapidly learning that the virus can have devastating effects on the heart and circulatory system and increase the risk of heart attacks and strokes.
By awarding flagship status to these projects, we hope to mobilise resources and research effort behind studies that have the best chance of swiftly improving care and saving lives. The speed at which we’ve done this is testament to the strength of UK cardiovascular science, and could lead to results within weeks.”
In one project, carried out through the new BHF Data Science Centre, multiple datasets from hospitals, GP surgeries and cardiovascular registries will be linked to give a unique insight into people with heart circulatory diseases who have suffered with Covid-19.
Professor Cathie Sudlow, Director of the BHF Data Science Centre, said:
“The answers to many questions about Covid-19 will lie in the data we’re gathering from patients. By combining datasets and making them safely available to world-leading researchers, we hope to quickly understand who is most at risk and what existing treatments might increase or reduce the damage caused by the disease.”
In another project, a team led from University College London (UCL) and the University of Bristol, is linking data from large cohort studies to uncover which cardiovascular diseases, as well as genetic, demographic or lifestyle factors are associated with increased risk of Covid-19 infection and its severity. It will also look at mechanisms linking Covid-19 to adverse cardiovascular health. This could pave the way for improved treatments or better ways of identifying those at risk.
Studies will also look at the damage the virus causes to the heart and circulatory system. Researchers led from UCL will set-up a registry to track the heart health complications caused by Covid-19, while another consortium of universities and hospitals led by investigators from Leeds and Oxford hope to follow people recovering for six months and use MR scans to assess longer-term damage to their heart and vital organs.
Scientists at the University of Oxford will use artificial intelligence techniques to assess CT scans to see if the virus causes long-term vascular inflammation. This could lead to wider use of anti-inflammatory treatments and other medicines to lower people’s future risk of heart attacks or strokes.
Finally, researchers will investigate how the pandemic has affected care for people with heart and circulatory diseases. This follows a sharp fall in non-Covid-19 admissions to hospital, including for heart attack and stroke.
The initiative builds on a pre-existing partnership between the BHF and NIHR. The research funders have awarded flagship status to peer-reviewed projects to avoid duplication of effort and maximise opportunities for collaboration and rapid results.
Professor Keith Channon, Chair of the NIHR-BHF Cardiovascular Partnership, said:
“Through the NIHR-BHF partnership, we’ve rapidly mobilised our existing scientific data, infrastructure and research community to answer important questions that could lead to improved ways of treating and caring for people with Covid-19. A positive from this devastating pandemic is that scientists are collaborating at a speed and scale we’ve never seen before. We’re only just starting to understand this disease and need to make rapid progress that will improve care for people in hospital, and in their recovery.”
Summary of projects
Using big data to understand the big picture
The project will link data on Covid-19 testing and cardiovascular health data in hospital and primary care datasets. This will enable researchers to carry out projects to understand why people with heart and circulatory disease are more at risk, how the virus might impact long-term cardiovascular health, and the impact of the pandemic on care for people with heart and circulatory diseases. The findings could therefore lead to improvements in treatment and care.
Led by Professor Cathie Sudlow, Director of the BHF Data Science Centre
What determines our risk of Covid-19?
Researchers will take large cohort studies where participants have already provided information about their general health and wellbeing and information on their genetic make-up. They will link these datasets with Covid-19 diagnosis and, in some cases to the results of swab and antibody testing in order to uncover which genetic, demographic or lifestyle factors that are associated with increased risk of Covid-19 infection and its severity.
Led by Professor Aroon Hingorani, Director of the UCL Institute of Cardiovascular Science and the UCL BHF Research Accelerator, Professor Deborah Lawlor, University of Bristol and Professor Cathie Sudlow
Can Covid-19 cause acute heart problems?
The research team will use hospital data from across the UK on the outcomes of people with Covid-19 to understand how cardiovascular disease and risk factors increase the risk of developing severe complications of Covid19 and which acute cardiovascular complications are most common in patients who develop Covid19. This UK project links with the European-wide Capacity-Covid project.
Led by Professor Bryan Williams, Director of the NIHR University College London Hospitals BRC
Using biomarkers to predict who will be most affected
Researchers will use routinely collected clinical data from patients tested for Covid -19 to see whether certain biomarkers (biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease) can predict those most likely to suffer severe complications as a result of the disease. This data will allow the researchers to establish whether commonly prescribed medications affect this risk. The team will also review the wider implications of the pandemic through investigating heart and circulatory disease admissions to hospital during the pandemic.
Led by Professor Jamil Mayet, Professor of Cardiology at Imperial College London
How does Covid-19 affect our organs?
Researchers hope to run two related projects that will follow nearly 1,000 patients from over a dozen hospitals across the UK recovering from relatively severe symptoms of Covid-19 infection. Detailed biomarker measurements and cardiac MR imaging will be carried out with follow-up scans at 6 months. In some of the participating centres, additional tests will be performed to image the damaging effects of the virus on the brain, lungs, liver and kidneys, and to assess patients’ exercise capacity and overall well-being. If funded, the trial will improve our understanding of the long term impact of Covid-19 on health and well-being, and shed light on which patients are most at risk of lasting complications.
Led by Professor John Greenwood, Cardiovascular Director of the NIHR Leeds CRF, and Professor Stefan Neubauer, Head of the Division of Cardiovascular Medicine and BRC Imaging Theme lead, University of Oxford and Oxford University Hospitals NHS Foundation Trust.
Using AI to see long-term effects on the heart
Many patients with severe Covid-19 infections will have a chest CT scan in hospital. Researchers will use new artificial intelligence techniques applied to these scans to accurately measure the level of inflammation in the vessels and surrounding tissues which might be caused by the virus. Repeat scans after infection has subsided will be compared to get a picture of inflammation during and after the infection. The Researchers are developing an early warning system to identify the patients at risk for adverse in-hospital outcomes, which will allow timely deployment of appropriate treatments and improve resources management within the NHS. They also hope to understand whether infection has lasting effects on vascular health and if extra medication should be given to reduce peoples’ risk of heart attacks or strokes in the months or years after the infection.
Led by Professor Charalambos Antoniades, BHF Senior Clinical Research Fellow and Professor of Cardiovascular Medicine at the University of Oxford
Notes to editors
To request interviews or for more information please call the BHF press office on 020 7554 0164 (07764 290 381 – out of hours) or email firstname.lastname@example.org
Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales, UK
5 January 2022
Overview With some ethnic minority groups and areas of deprivation suffering higher levels of severe outcomes from COVID-19, it is all the more important to ensure equitable access to, and uptake...
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
14 September 2021
Overview As the rollout of first dose COVID-19 vaccines accelerated in the UK and Europe, safety concerns emerged after reports that a small number of people experienced adverse events in their...
Understanding and responding to COVID-19 in Wales: protocol for a privacy-protecting data platform for enhanced epidemiology and evaluation of interventions
14 May 2021
Jane Lyons and colleagues have created a platform using population level cohorts, and other linked data sources, to provide up-to-date insights to the Welsh government.